Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

Trial Profile

Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Chenodeoxycholic acid (Primary) ; Resveratrol
  • Indications Paraplegia
  • Focus Therapeutic Use
  • Acronyms SPA-M
  • Most Recent Events

    • 03 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Feb 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 19 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top